Evidence map›Paper›PMID 40590562›Full record

ArticleJournal of clinical microbiology2025

Development and validation of next-generation sequencing-based clinical test for triazole resistance prediction in

J R Caldera, Ashley Dayo, Nathan Wiederhold, Shangxin Yang

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

J R CalderaDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA Health, Los Angeles, California, USA.ORCID 0000-0003-0563-8815
Ashley DayoDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA Health, Los Angeles, California, USA.
Nathan WiederholdDepartment of Pathology and Laboratory Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID 0000-0002-2225-5122
Shangxin YangDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA Health, Los Angeles, California, USA.ORCID 0000-0001-9991-1178

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rising rates of triazole drug resistance in

Indexed as

Antifungal AgentsAspergillus fumigatusDrug Resistance, FungalHigh-Throughput Nucleotide SequencingTriazolesAspergillosisCytochrome P-450 Enzyme SystemFungal ProteinsGenotypeHumansMicrobial Sensitivity TestsMutationNitrilesPyridinesAntifungal Agentscytochrome P-450 CYP51A, AspergillusCytochrome P-450 Enzyme SystemFungal ProteinsisavuconazoleNitrilesPyridinesTriazolesantifungal resistanceantifungal susceptibility testingAspergillus fumigatusazole resistancecyp51A mutationsgenotypingnext-generation sequencingwhole-genome sequencing

Identifiers

PMID40590562
PMCPMC12345187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.